KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash: 2017-2025

Historic Change in Cash for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $154.7 million.

  • Amneal Pharmaceuticals' Change in Cash rose 438.71% to $154.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.1 million, marking a year-over-year increase of 1027.25%. This contributed to the annual value of $19.3 million for FY2024, which is 69.77% down from last year.
  • Amneal Pharmaceuticals' Change in Cash amounted to $154.7 million in Q3 2025, which was up 912.80% from $15.3 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Change in Cash's 5-year high stood at $154.7 million during Q3 2025, with a 5-year trough of -$172.7 million in Q2 2021.
  • In the last 3 years, Amneal Pharmaceuticals' Change in Cash had a median value of $3.5 million in 2023 and averaged $18.5 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Change in Cash plummeted by 728.24% in 2023, and later surged by 1,045.00% in 2024.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Change in Cash stood at -$53.9 million in 2021, then declined by 12.59% to -$60.7 million in 2022, then spiked by 105.77% to $3.5 million in 2023, then skyrocketed by 1,045.00% to $40.1 million in 2024, then spiked by 438.71% to $154.7 million in 2025.
  • Its Change in Cash stands at $154.7 million for Q3 2025, versus $15.3 million for Q2 2025 and -$50.0 million for Q1 2025.